## NSAID-Induced Peptic Ulcer Disease: Management Strategy **Key Point:** In patients with NSAID-induced peptic ulcer disease who require ongoing anti-inflammatory therapy, the safest approach combines a COX-2 selective inhibitor (coxib) with a proton pump inhibitor (PPI). ### Risk Stratification for NSAID Ulcer Complications This patient has **high-risk features** for NSAID-induced ulcer: - Age >50 years - Long-term NSAID use (3 years) - Previous ulcer/GI bleed (now documented) - Female gender **High-Yield:** Patients with prior NSAID-induced GI bleeding have a **10–15% annual recurrence rate** if NSAIDs are continued without gastroprotection. ### Comparative Strategies for NSAID Continuation | Strategy | Mechanism | Efficacy | Limitations | Cost | |----------|-----------|----------|-------------|------| | **Non-selective NSAID + PPI** | PPI ↓ acid; NSAID still inhibits COX-1 in stomach | ~70% ulcer prevention | Incomplete protection; COX-1 inhibition persists | Low | | **COX-2 selective (coxib) + PPI** | Coxib spares gastric COX-1; PPI ↓ acid | ~95% ulcer prevention | Cardiovascular risk with coxibs; requires monitoring | Moderate | | **Non-selective NSAID + Misoprostol** | Misoprostol ↑ PGE₁; NSAID still inhibits COX-1 | ~80% ulcer prevention | GI side effects (diarrhea); poor compliance | Moderate | | **Acetaminophen alone** | No COX inhibition; no ulcer risk | 100% ulcer prevention | Inadequate anti-inflammatory effect for RA | Low | ### Why Celecoxib + PPI Is Optimal Here **Mechanism of COX-2 Selectivity:** COX-2 selective inhibitors (celecoxib, etoricoxib) preferentially inhibit the inducible COX-2 enzyme found in inflammatory tissues, while sparing COX-1 in the gastric mucosa. COX-1 produces protective prostaglandins (PGE₂, PGI₂) that: - Stimulate mucus secretion - Maintain mucosal blood flow - Promote bicarbonate secretion - Enhance epithelial cell proliferation By preserving gastric COX-1 function, coxibs reduce ulcer risk by **60–70%** compared to non-selective NSAIDs, even without a PPI. Adding a PPI provides additional acid suppression and further reduces recurrence. **Clinical Pearl:** The combination of a COX-2 selective inhibitor + PPI is endorsed by major guidelines (ACG, ASGE) for high-risk patients requiring ongoing NSAID therapy after a documented GI bleed. ### Cardiovascular Considerations **Warning:** COX-2 selective inhibitors carry an increased risk of myocardial infarction and stroke, particularly with long-term use. However, in this patient: - The cardiovascular risk of coxibs is **lower than the GI bleeding risk** of continuing non-selective NSAIDs without adequate gastroprotection - Celecoxib at 200 mg twice daily is a moderate dose - Baseline cardiovascular assessment should be performed **Mnemonic for NSAID GI Risk Reduction: "COX-2 + PPI"** - **C**elecoxib (or other coxib) - **O**meprazole (or other PPI) - **X**-out the risk - **2** = COX-**2** selective - **P**roton pump inhibitor - **I**nhibitor ### Why Other Options Are Suboptimal **Option 1 (Naproxen + PPI):** While a PPI provides some protection, a non-selective NSAID still inhibits gastric COX-1, leaving the mucosa vulnerable. Recurrence risk remains ~15–20% annually. **Option 4 (Naproxen + Misoprostol):** Misoprostol is effective but causes diarrhea in 15–30% of patients, leading to poor compliance. It is also contraindicated in pregnancy (relevant for some patients). Less effective than PPI + coxib combination. **Option 2 (Acetaminophen alone):** Acetaminophen has minimal anti-inflammatory effect and is inadequate for managing active rheumatoid arthritis. Switching entirely off NSAIDs is appropriate only if the patient's inflammatory disease can be controlled with other agents (DMARDs, biologics).
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.